TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. PY - 2015 DA - 2015// TI - Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 JO - Int J Cancer. VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2015 ER - TY - JOUR AU - Koizumi, W. AU - Narahara, H. AU - Hara, T. AU - Takagane, A. AU - Akiya, T. AU - Takagi, M. PY - 2008 DA - 2008// TI - S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial JO - Lancet Oncol. VL - 9 UR - https://doi.org/10.1016/S1470-2045(08)70035-4 DO - 10.1016/S1470-2045(08)70035-4 ID - Koizumi2008 ER - TY - JOUR AU - Fujitani, K. AU - Yang, H. K. AU - Mizusawa, J. AU - Kim, Y. W. AU - Terashima, M. AU - Han, S. U. PY - 2016 DA - 2016// TI - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00553-7 DO - 10.1016/S1470-2045(15)00553-7 ID - Fujitani2016 ER - TY - JOUR AU - Harada, K. AU - Mizrak Kaya, D. AU - Shimodaira, Y. AU - Ajani, J. A. PY - 2017 DA - 2017// TI - Global chemotherapy development for gastric cancer JO - Gastric Cancer. VL - 20 UR - https://doi.org/10.1007/s10120-016-0655-8 DO - 10.1007/s10120-016-0655-8 ID - Harada2017 ER - TY - JOUR AU - Bang, Y. J. AU - Cutsem, E. AU - Feyereislova, A. AU - Chung, H. C. AU - Shen, L. AU - Sawaki, A. PY - 2010 DA - 2010// TI - Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial JO - Lancet. VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61121-X DO - 10.1016/S0140-6736(10)61121-X ID - Bang2010 ER - TY - JOUR AU - Fuchs, C. S. AU - Tomasek, J. AU - Yong, C. J. AU - Dumitru, F. AU - Passalacqua, R. AU - Goswami, C. PY - 2014 DA - 2014// TI - Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial JO - Lancet. VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61719-5 DO - 10.1016/S0140-6736(13)61719-5 ID - Fuchs2014 ER - TY - JOUR AU - Wilke, H. AU - Muro, K. AU - Cutsem, E. AU - Oh, S. C. AU - Bodoky, G. AU - Shimada, Y. PY - 2014 DA - 2014// TI - Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial JO - Lancet Oncol. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70420-6 DO - 10.1016/S1470-2045(14)70420-6 ID - Wilke2014 ER - TY - JOUR AU - Wang, K. AU - Yuen, S. T. AU - Xu, J. AU - Lee, S. P. AU - Yan, H. H. N. AU - Shi, S. T. PY - 2014 DA - 2014// TI - Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer JO - Nat Genet. VL - 46 UR - https://doi.org/10.1038/ng.2983 DO - 10.1038/ng.2983 ID - Wang2014 ER - TY - JOUR AU - Kakiuchi, M. AU - Nishizawa, T. AU - Ueda, H. AU - Gotoh, K. AU - Tanaka, A. AU - Hayashi, A. PY - 2014 DA - 2014// TI - Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma JO - Nat Genet. VL - 46 UR - https://doi.org/10.1038/ng.2984 DO - 10.1038/ng.2984 ID - Kakiuchi2014 ER - TY - JOUR PY - 2014 DA - 2014// TI - Comprehensive molecular characterization of gastric adenocarcinoma JO - Nature VL - 513 UR - https://doi.org/10.1038/nature13480 DO - 10.1038/nature13480 ID - ref10 ER - TY - JOUR AU - Chen, K. AU - Yang, D. AU - Li, X. AU - Sun, B. AU - Song, F. AU - Cao, W. PY - 2015 DA - 2015// TI - Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy JO - Proc Natl Acad Sci U S A. VL - 112 UR - https://doi.org/10.1073/pnas.1422640112 DO - 10.1073/pnas.1422640112 ID - Chen2015 ER - TY - JOUR AU - Cristescu, R. AU - Lee, J. AU - Nebozhyn, M. AU - Kim, K. M. AU - Ting, J. C. AU - Wong, S. S. PY - 2015 DA - 2015// TI - Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes JO - Nat Med. VL - 21 UR - https://doi.org/10.1038/nm.3850 DO - 10.1038/nm.3850 ID - Cristescu2015 ER - TY - JOUR AU - Kuboki, Y. AU - Yamashita, S. AU - Niwa, T. AU - Ushijima, T. AU - Nagatsuma, A. AU - Kuwata, T. PY - 2016 DA - 2016// TI - Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer JO - Ann Oncol. VL - 27 UR - https://doi.org/10.1093/annonc/mdv508 DO - 10.1093/annonc/mdv508 ID - Kuboki2016 ER - TY - JOUR AU - Horak, P. AU - Fröhling, S. AU - Glimm, H. PY - 2016 DA - 2016// TI - Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls JO - ESMO Open. VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000094 DO - 10.1136/esmoopen-2016-000094 ID - Horak2016 ER - TY - JOUR AU - Nagahashi, M. AU - Wakai, T. AU - Shimada, Y. AU - Ichikawa, H. AU - Kameyama, H. AU - Kobayashi, T. PY - 2016 DA - 2016// TI - Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine JO - Genome Med. VL - 8 UR - https://doi.org/10.1186/s13073-016-0387-8 DO - 10.1186/s13073-016-0387-8 ID - Nagahashi2016 ER - TY - BOOK AU - Sobin, L. H. AU - Gospodarowicz, M. K. AU - Wittekind, C. PY - 2010 DA - 2010// TI - TNM classification of malignant tumours (Uicc International Union Against Cancer) PB - Wiley-Blackwell CY - Oxford ID - Sobin2010 ER - TY - JOUR AU - Li, H. AU - Durbin, R. PY - 2009 DA - 2009// TI - Fast and accurate short read alignment with Burrows-Wheeler transform JO - Bioinformatics. VL - 25 UR - https://doi.org/10.1093/bioinformatics/btp324 DO - 10.1093/bioinformatics/btp324 ID - Li2009 ER - TY - JOUR AU - Li, H. PY - 2012 DA - 2012// TI - Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly JO - Bioinformatics. VL - 28 UR - https://doi.org/10.1093/bioinformatics/bts280 DO - 10.1093/bioinformatics/bts280 ID - Li2012 ER - TY - JOUR AU - Eifert, C. AU - Pantazi, A. AU - Sun, R. AU - Xu, J. AU - Cingolani, P. AU - Heyer, J. PY - 2017 DA - 2017// TI - Clinical application of a cancer genomic profiling assay to guide precision medicine decisions JO - Per Med. VL - 14 UR - https://doi.org/10.2217/pme-2017-0011 DO - 10.2217/pme-2017-0011 ID - Eifert2017 ER - TY - JOUR AU - Brock, G. AU - Pihur, V. AU - Datta, S. S. AU - Datta, S. S. PY - 2008 DA - 2008// TI - clValid: an R package for cluster validation JO - J Stat Softw VL - 25 UR - https://doi.org/10.18637/jss.v025.i04 DO - 10.18637/jss.v025.i04 ID - Brock2008 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science. VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Greulich, H. AU - Kaplan, B. AU - Mertins, P. AU - Chen, T. AU - Tanaka, K. E. AU - Yun, C. PY - 2012 DA - 2012// TI - Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 JO - Proc Natl Acad Sci U S A. VL - 109 UR - https://doi.org/10.1073/pnas.1203201109 DO - 10.1073/pnas.1203201109 ID - Greulich2012 ER - TY - JOUR AU - Bose, R. AU - Kavuri, S. M. AU - Searleman, A. C. AU - Shen, W. AU - Shen, D. AU - Koboldt, D. C. PY - 2013 DA - 2013// TI - Activating HER2 mutations in HER2 gene amplification negative breast cancer JO - Cancer Discov. VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-12-0349 DO - 10.1158/2159-8290.CD-12-0349 ID - Bose2013 ER - TY - JOUR AU - Chumsri, S. AU - Weidler, J. AU - Ali, S. AU - Balasubramanian, S. AU - Wallweber, G. AU - Fazio-Eli, L. PY - 2015 DA - 2015// TI - Prolonged response to trastuzumab in a patient with HER2-nonamplified breast cancer with elevated HER2 dimerization harboring an ERBB2 S310F mutation JO - J Natl Compr Canc Netw. VL - 13 UR - https://doi.org/10.6004/jnccn.2015.0132 DO - 10.6004/jnccn.2015.0132 ID - Chumsri2015 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. AU - Tutt, A. N. J. AU - Johnson, D. A. AU - Richardson, T. B. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature. VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Bouwman, P. AU - Jonkers, J. PY - 2012 DA - 2012// TI - The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance JO - Nat Rev Cancer. VL - 12 UR - https://doi.org/10.1038/nrc3342 DO - 10.1038/nrc3342 ID - Bouwman2012 ER - TY - JOUR AU - Bang, Y. J. AU - Im, S. A. AU - Lee, K. W. AU - Cho, J. Y. AU - Song, E. K. AU - Lee, K. H. PY - 2015 DA - 2015// TI - Randomized, double-blind Phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer JO - J Clin Oncol. VL - 33 UR - https://doi.org/10.1200/JCO.2014.60.0320 DO - 10.1200/JCO.2014.60.0320 ID - Bang2015 ER - TY - JOUR AU - Bang, Y. J. AU - Boku, N. AU - Chin, K. W. AU - Lee, S. H. AU - Park, S. AU - Qin, S. Y. PY - 2016 DA - 2016// TI - Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study JO - Ann Oncol VL - 27 ID - Bang2016 ER - TY - JOUR AU - Tsuchida, N. AU - Murugan, A. K. AU - Grieco, M. PY - 2016 DA - 2016// TI - Kirsten Ras* oncogene: significance of its discovery in human cancer research JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.8773 DO - 10.18632/oncotarget.8773 ID - Tsuchida2016 ER - TY - JOUR AU - Cox, A. D. AU - Fesik, S. W. AU - Kimmelman, A. C. AU - Luo, J. AU - Der, C. J. PY - 2014 DA - 2014// TI - Drugging the undruggable RAS: mission possible? JO - Nat Rev Drug Discov. VL - 13 UR - https://doi.org/10.1038/nrd4389 DO - 10.1038/nrd4389 ID - Cox2014 ER - TY - JOUR AU - Rahman, M. T. AU - Nakayama, K. AU - Rahman, M. AU - Katagiri, H. AU - Katagiri, A. AU - Ishibashi, T. PY - 2013 DA - 2013// TI - KRAS and MAPK1 gene amplification in type II ovarian carcinomas JO - Int J Mol Sci. VL - 14 UR - https://doi.org/10.3390/ijms140713748 DO - 10.3390/ijms140713748 ID - Rahman2013 ER - TY - JOUR AU - Blumenschein, G. R. AU - Smit, E. F. AU - Planchard, D. AU - Kim, D. W. AU - Cadranel, J. AU - Pas, T. PY - 2015 DA - 2015// TI - A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) JO - Ann Oncol. VL - 26 UR - https://doi.org/10.1093/annonc/mdv072 DO - 10.1093/annonc/mdv072 ID - Blumenschein2015 ER - TY - JOUR AU - Sherr, C. J. AU - Beach, D. AU - Shapiro, G. I. PY - 2016 DA - 2016// TI - Targeting CDK4 and CDK6: from discovery to therapy JO - Cancer Discov. VL - 6 UR - https://doi.org/10.1158/2159-8290.CD-15-0894 DO - 10.1158/2159-8290.CD-15-0894 ID - Sherr2016 ER - TY - JOUR AU - Wiedemeyer, W. R. AU - Dunn, I. F. AU - Quayle, S. N. AU - Zhang, J. AU - Chheda, M. G. AU - Dunn, G. P. PY - 2010 DA - 2010// TI - Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM JO - Proc Natl Acad Sci U S A. VL - 107 UR - https://doi.org/10.1073/pnas.1001613107 DO - 10.1073/pnas.1001613107 ID - Wiedemeyer2010 ER - TY - JOUR AU - Konecny, G. E. AU - Winterhoff, B. AU - Kolarova, T. AU - Qi, J. AU - Manivong, K. AU - Dering, J. PY - 2011 DA - 2011// TI - Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer JO - Clin Cancer Res. VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2307 DO - 10.1158/1078-0432.CCR-10-2307 ID - Konecny2011 ER - TY - JOUR AU - Young, R. J. AU - Waldeck, K. AU - Martin, C. AU - Foo, J. H. AU - Cameron, D. P. AU - Kirby, L. PY - 2014 DA - 2014// TI - Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines JO - Pigment Cell Melanoma Res. VL - 27 UR - https://doi.org/10.1111/pcmr.12228 DO - 10.1111/pcmr.12228 ID - Young2014 ER - TY - JOUR AU - Gao, J. AU - Adams, R. P. AU - Swain, S. M. PY - 2015 DA - 2015// TI - Does CDKN2A loss predict palbociclib benefit? JO - Curr Oncol. VL - 22 UR - https://doi.org/10.3747/co.22.2700 DO - 10.3747/co.22.2700 ID - Gao2015 ER - TY - JOUR AU - Berns, K. AU - Horlings, H. M. AU - Hennessy, B. T. AU - Madiredjo, M. AU - Hijmans, E. M. AU - Beelen, K. PY - 2007 DA - 2007// TI - A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer JO - Cancer Cell. VL - 12 UR - https://doi.org/10.1016/j.ccr.2007.08.030 DO - 10.1016/j.ccr.2007.08.030 ID - Berns2007 ER - TY - JOUR AU - Mohd Sharial, M. S. AU - Crown, J. AU - Hennessy, B. T. PY - 2012 DA - 2012// TI - Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer JO - Ann Oncol. VL - 23 UR - https://doi.org/10.1093/annonc/mds200 DO - 10.1093/annonc/mds200 ID - Mohd Sharial2012 ER - TY - JOUR AU - Zuo, Q. AU - Liu, J. AU - Zhang, J. AU - Wu, M. AU - Guo, L. AU - Liao, W. PY - 2015 DA - 2015// TI - Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance JO - Sci Rep. VL - 5 UR - https://doi.org/10.1038/srep11634 DO - 10.1038/srep11634 ID - Zuo2015 ER - TY - JOUR AU - Kelly, C. M. AU - Janjigian, Y. Y. PY - 2016 DA - 2016// TI - The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond JO - J Gastrointest Oncol. VL - 7 UR - https://doi.org/10.21037/jgo.2016.06.10 DO - 10.21037/jgo.2016.06.10 ID - Kelly2016 ER - TY - JOUR AU - Lee, J. Y. AU - Hong, M. AU - Kim, S. T. AU - Park, S. H. AU - Kang, W. K. AU - Kim, K. M. PY - 2015 DA - 2015// TI - The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer JO - Sci Rep. VL - 5 UR - https://doi.org/10.1038/srep09289 DO - 10.1038/srep09289 ID - Lee2015 ER - TY - JOUR AU - Alexandrov, L. B. AU - Nik-Zainal, S. AU - Siu, H. C. AU - Leung, S. Y. AU - Stratton, M. R. PY - 2015 DA - 2015// TI - A mutational signature in gastric cancer suggests therapeutic strategies JO - Nat Commun. VL - 6 UR - https://doi.org/10.1038/ncomms9683 DO - 10.1038/ncomms9683 ID - Alexandrov2015 ER - TY - JOUR AU - Sahasrabudhe, R. AU - Lott, P. AU - Bohorquez, M. AU - Toal, T. AU - Estrada, A. P. AU - Suarez, J. J. PY - 2017 DA - 2017// TI - Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer JO - Gastroenterology VL - 152 UR - https://doi.org/10.1053/j.gastro.2016.12.010 DO - 10.1053/j.gastro.2016.12.010 ID - Sahasrabudhe2017 ER - TY - JOUR AU - Konstantinopoulos, P. A. AU - Ceccaldi, R. AU - Shapiro, G. I. AU - D’Andrea, A. D. PY - 2015 DA - 2015// TI - Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer JO - Cancer Discov. VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0714 DO - 10.1158/2159-8290.CD-15-0714 ID - Konstantinopoulos2015 ER - TY - JOUR AU - Telli, M. L. AU - Timms, K. M. AU - Reid, J. AU - Hennessy, B. AU - Mills, G. B. AU - Jensen, K. C. PY - 2016 DA - 2016// TI - Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer JO - Clin Cancer Res. VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2477 DO - 10.1158/1078-0432.CCR-15-2477 ID - Telli2016 ER - TY - JOUR AU - Lee, Y. S. AU - Cho, Y. S. AU - Lee, G. K. AU - Lee, S. AU - Kim, Y. W. AU - Jho, S. PY - 2014 DA - 2014// TI - Genomic profile analysis of diffuse-type gastric cancers JO - Genome Biol. VL - 15 UR - https://doi.org/10.1186/gb-2014-15-4-r55 DO - 10.1186/gb-2014-15-4-r55 ID - Lee2014 ER -